Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-11-28
2010-06-29
Goldberg, Jeannie A (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07745132
ABSTRACT:
A method of identifying an animal having a disease or condition without clinical symptoms includes detecting an elevated level of plasma DNA from blood or a blood fraction from the animal. In particular, the disease or condition can be a lymphoid neoplastic disease. Also, the plasma DNA can comprise a tumor-derived plasma DNA. In certain embodiments, the evaluation of the blood or blood fraction from the animal for the mutation assists in the identification of the disease or condition and/or its prognosis in the animal.
REFERENCES:
Deligezer et al. (Clinica Chimica Acta, vol. 335, pp. 89-94, 2003).
Lee et al. (Cancer, vol. 77, No. 9, pp. 1892-1898, 1996).
Fournel-Fleury et al. (J. Comp. Path. vol. 117, pp. 35-59, 1997).
Starkey et al. (Briefings in Functional Genomics and Proteomics, vol. 4, No. 2, pp. 112-128, Jul. 2005).
Mulcahy et al. (Clinical Cancer Research, vol. 4, pp. 271-275, Feb. 1998).
Oliver Gautschi, et al., Circulating Deoxyribonucleic Acid As Prognostic Marker in Non-Small-Cell Lung Cancer Patients Undergoing Chemotherapy, Journal of Clinical Oncology, vol. 22, No. 20, Oct. 15, 2004, pp. 4157-4164.
Ning Ren, et al., The Prognostic Value of Circulating Plasma DNA Level and Its Allelic Imbalance on Chromosome 8p In Patients With Hepatocellular Carcinoma, J Cancer Res Clin Oncol (2006) 132; pp. 399-407.
Sabine Jahr, et al., DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin From Apoptotic and Necrotic Cells, Cancer Research 61, pp. 1659-1665, Feb. 15, 2001.
Kyle D. Weaver, et al., Methylated Tumor-Specific DNA As a Plasma Biomarker in Patients With Glioma, Cancer Investigation 24:35-40, (2006).
Bret Taback, et al., Quantification of Circulatin DNA in the Plasma and Serum of Cancer Patients, Ann, N.Y. Acad. Sci. 1022: pp. 17-24 (2004).
Tsu-Lan Wu, et al., Cell-Free DNA: Measurement in Various Carcinomas and Establishment of Normal Reference Range, Clinica Chimica Acta 321 (2002), pp. 77-87.
Frank Diehl, et al., Detection and Quantification of Mutations in the Plasma of Patients With Colorectal Tumors, PNAS, Nov. 8, 2005, vol. 102, No. 45, pp. 16368-16373.
Hannes M. Muller, et al., Prognostic DNA Methylation Marker in Serum of Cancer Patients, Ann, N.Y. Acad. Sci. 1022: 44-49 (2004).
Andreas Widschwendter, et al., DNA Methylation in Serum and Tumors of Cervical Cancer Patients, Clinical Cancer Research, vol. 10, pp. 565-571, Jan. 15, 2004.
Gabriella Sozzi, et al., Analysis of Circulating Tumor DNA in Plasma At Diagnosis and During Follow-Up of Lung Cancer Patients, Cancer Research 61, pp. 4675-4678, Jun. 15, 2001.
N. Frickhofen et al., Rearranged Lg Heavy Chain DNA Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia, Blood, 1997, vol. 90, pp. 4953-4960.
Anthony T.C. Chan, et al., Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal Carcinoma, Journal of the National Cancer Institute, vol. 94, pp. 1614-1619, No. 21, Nov. 6, 2002.
Anna Rogers, et al., Relative Increase in Leukemia-Specific DNA in Peripheral Blood Plasma From Patients Wtih Acute Myeloid Leukemia and Myelodysplasia, Blood, 2004, pp. 2799-2801.
M. Galeazzi et al., Dosage and Characterization of Circulating DNA: Present Usuage and Possible Applications in Systemic Autoimmune Disorders, Autoimmunity Reviews 2 (2003), pp. 50-55.
Dolores C. Garcia-Olmo et al., Detection of Circulating Tumor Cells and of Tumor DNA in Plasma During Tumor Progression in Rats, Cancer Letters 217 (2005), pp. 115-123.
Luis J. Herrera, et al., Quantitative Analysis of Circulating Plasma DNA As a Tumor Marker in Thoracic Malignancies, Clinical Chemistry 51:1, pp. 113-118 (2005).
Monika Jung, et al., Changes in Concentration of DNA in Serum and Plasma During Storage of Blood Samples, Clinical Chemistry 49, No. 6, 2003, pp. 1028-1029.
Victoria L. Singer, et al., Characterization of PicoGreen Reagent and Development of a Fluorescence-Based Solution Assay for Double-Stranded DNA Quantitation, Analytical Biochemistry 249, pp. 228-238 (1997).
R.C. Burnett et al., Diagnosis of Canine Lymphoid Neoplasia Using Clonal Rearrangements of Antigen Receptor Genes, Veterinary Pathology, 40:32, pp. 32-41, (2003).
D. Schaefer et al., American Society for Veterinary Clinical Pathology (ASVCP) 40th Annual Meeting, Abstract #15, “Circulating Nucleic Acids As a Biomarker for Dogs With Cancer”, Sep. 2005, p. 285.
D.M.W. Schaefer, et al., Quantification of Plasma DNA As a Prognostic Indicator in Canine Lymphoid Neoplasia, The Authors, Journal Compilation, Veterinary and Comparative Oncology, (2007), pp. 145-155.
Lana, Susan E. et al., Utility of Polymerase Chain Reaction for Analysis of Antigen Receptor Rearrangement in Staging and Predicting Prognosis in Dogs With Lymphoma, J. Vet Intern Med 2006, 20, pp. 329-334.
Goldberg Jeannie A
MacMillan Sobanski & Todd LLC
The Ohio State University
LandOfFree
Prognostic indicators of canine lymphoid neoplasia using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prognostic indicators of canine lymphoid neoplasia using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prognostic indicators of canine lymphoid neoplasia using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4239715